Results Preview: Scrip's Pharma Watchlist
This article was originally published in Scrip
Executive Summary
Johnson & Johnson will kick off the big pharma financial results season on Jan. 26. The backdrop for the company's conference call on its earnings will be the restructuring of its medical devices business. On Jan. 19 it announced it would cut around 3,000 jobs to make savings of $800m-1bn. That will involve one-off charges of $2-2.4bn with about $600m to be lodged in the books of the fourth quarter just gone. J&J has promised additional details of the impact of its changes during its earnings call.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.